The Street InsiderGilead Sciences (GILD) Price Target Raised to $115 at RBC Capital
Article Stock Quotes (1) Comments (0)
RBC Capital maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) and raised its price taget to $115.00 (from $102.00). Analyst Michael J. Yee is positive on its next-gen HIV pill, with Phase II on tap next month.
long & holding.
August 18, 2014
Achillion Pharmaceuiticals: Why Deutsche Bank Says Buy
We know it was tested vs. Gilead’s nuke in preclinical models & showed higher potency in GT3 (~7 fold greater).
China building charging stations in every city that are not compatible to TSLA. China wants China EV s not US EV s
Last earnings Transcript:
Kandi Technologies Announces Second Quarter 2014 Financial ResultsKandi Technologies, Corp. August GlobeNewswire
CEO " Robust EV Sales Growth Ahead of Us"
very cheap here.
This is my kind of chart, no resistance with green bars. "Selfies" making 1,000's of new clients everyday.
Kandi Technologies Corp. (KNDI) receives an order valued at RMB4.1 million
($604,000) for 60 of the Chinese recreational and electric vehicle maker's
all-electric low-speed vehicles from Hangzhou's postal service.
Analyst Rating Network ( ICPT )
August 12, 2014, 11:00 A.M. ET
Intercept Pharmaceuticals: Home Run
By Ben Levisohn
RBC’s Michael Yee and team explain why investors are so excited about Intercept’s results:
We would also consider these interesting upside drivers: 1) As we have written previously, we can’t deny this isn’t a potential acquisition candidate for liver-focused companies such as Johnson & Johnson (JNJ), Britol-Myers Squibb (BMY), Merck (MRK), Gilead Sciences (GILD), etc., and this drug could move the needle and have considerable synergy;